The Adoption Paradox

After 25 years in the diagnostic and medical device industry, having entered the space in 2002, I have observed a fundamental shift in the market entry window. This briefing explores why technical validation is no longer the primary hurdle for diagnostic and medical device adoption.

The real challenge is structural: the gap between FDA clearance and sustainable clinical revenue. We call this The Adoption Paradox.

Core Thesis

Clearance does not create adoption. The real challenge begins after validation.

Most diagnostic and medical device companies believe that FDA clearance is the hardest milestone.

It is not.

The real challenge begins after clearance, when diagnostic and medical device companies attempt to convert clinical validation into real-world adoption. This is where most products stall: not because the science is wrong, but because the commercial architecture was never built.

This gap is what we define as the market entry window.

Diagnostic and MedTech founders, investors, and even experienced operators often anchor on a flawed assumption:

Strong clinical performance will naturally lead to market adoption.

In reality, adoption is not driven by performance alone. It is driven by alignment across multiple systems:

• Clinical workflow integration
• Reimbursement and payer coverage architecture
• Economic value to the provider
• Channel access and distribution infrastructure
• Physician behavior and guideline integration

If these are not intentionally designed, even the most clinically accurate test or device will struggle to gain traction.

Evidence Designed for Regulators, Not Buyers

Most clinical studies are designed to achieve clearance, not adoption.

They demonstrate analytical performance and clinical validity, but fail to answer the questions that matter to:

• Payers: Does this reduce cost or improve outcomes
• Providers: Does this change how I treat patients
• Health systems: Does this improve throughput or reduce burden

Without clinical utility and economic evidence, adoption stalls.

Reimbursement Infrastructure Gaps

Many companies treat reimbursement as a post-clearance activity.

This is one of the most common and most costly structural failures.

Without a clear plan for coding, coverage, and payment, providers are left with uncertainty. Uncertainty kills utilization.

Placement Strategy Ambiguity

Where does the test or device live?

• Central lab
• Hospital lab
• Point of care
• Decentralized or home

Each setting has different buyers, economics, and workflow constraints.

Without a clear placement decision, strategy becomes diluted and ineffective.

Commercial Infrastructure Deficits

Distribution is not logistics. It is market access.

Without alignment at the distributor and field level, products fail to reach the right accounts or generate consistent utilization.

Pilot Programs Without Scale Architecture

Pilot programs create early traction, but they are not designed for scale.

Without standardized workflows, reimbursement clarity, and a repeatable sales motion, pilots remain isolated successes.

FDA clearance proves one thing: the test or device works. It demonstrates analytical validity and, in many cases, clinical validity. But clearance does not answer the questions that drive adoption.

Payers do not reimburse products because they are accurate. They reimburse products that change clinical decisions and improve patient outcomes. This distinction between validity (does it measure what it claims?) and utility (does it change what clinicians do?) is the single most misunderstood dynamic in diagnostic and MedTech market entry.

Without clinical utility evidence, payer coverage decisions stall. Without coverage, providers absorb financial risk. Without financial clarity, utilization collapses.

Strategic Key Takeaway

3 Data Points Every Payer Actually Wants

• Clinical utility evidence: proof the test or device changes treatment decisions or patient management pathways.
• Economic impact data: demonstrated reduction in downstream costs, unnecessary procedures, or hospitalizations.
• Comparative effectiveness: evidence that the product outperforms or meaningfully adds to existing alternatives.

Even when the evidence is strong and reimbursement is secured, adoption can fail at the point of care. This is the physician workflow challenge: the physical and digital "last mile" of diagnostic and device integration.

A 15-minute patient encounter leaves no room for ambiguity. If the result does not flow seamlessly into the EMR, if the ordering process adds friction, if the turnaround time does not align with the clinical decision window, physicians will default to existing behavior.

Adoption infrastructure must account for how the product is ordered, how the result is delivered, how it integrates into existing clinical workflows, and how it fits into the rhythm of care delivery. This is not a technology problem. It is a design problem.

Companies that treat workflow integration as a post-launch optimization consistently underestimate the resistance they will encounter. The product that is easiest to use will win, not the one that is most analytically precise.

Are you entering the market entry window?

For decades, the diagnostic and medical device industry has optimized for a single objective: proving that a product works. Analytical sensitivity, specificity, and reproducibility have been the benchmarks of success, and for good reason. Without rigorous validation, no product earns the right to enter the clinical setting.

But validation is a necessary condition, not a sufficient one. The market has shifted. Payers, health systems, and clinicians are no longer asking "does this test work?" They are asking "does this test change what I do?"

This is the shift from validation to utility. It requires companies to move beyond the laboratory and into the clinical decision pathway. Products must demonstrate not only that they detect a condition accurately, but that the detection leads to a measurable change in patient management, treatment selection, or clinical outcomes.

Companies that recognize this shift early gain a structural advantage. They design their evidence strategies around utility from the start, embedding health economics and outcomes research alongside clinical trials. They build the case for reimbursement before clearance, not after.

Those that do not make this shift find themselves in a familiar position: cleared, validated, and commercially stranded.

The Cost of Delayed Commercial Architecture

The most expensive mistake in diagnostic and MedTech market entry is not a failed study or a rejected submission. It is the 18 to 24 months of post-clearance stagnation that occurs when commercial architecture is treated as a post-regulatory activity.

When regulatory, clinical, and payer teams operate in sequence rather than in parallel, critical dependencies are missed. Evidence gaps are discovered after clearance. Reimbursement strategy begins without the data payers require. Channel partnerships are formed without clear economic models. The result is what we call the post-clearance plateau: a period of high burn and low utilization that erodes investor confidence and market position.

Early alignment between these teams is the defining characteristic of companies that achieve sustainable adoption. This is the AdvisoryDx approach: designing commercial architecture alongside clinical and regulatory development, not after it.

Companies that sequence market entry strategically compress time-to-revenue, reduce capital requirements, and build defensible market positions before competitors reach the same clinical endpoints.

The Gap Between Clearance and Adoption

Most companies are built for validation. Few are built for adoption.

This is the structural failure point in diagnostics and medical devices.

These breakdowns are not random. They are systemic.

Diagnostic and medical device companies are built to solve for science, engineering, and regulatory approval.

But adoption requires a different system entirely.

It requires commercial architecture.

This includes:

• Evidence strategy aligned to payer and provider decision-making
• A defined reimbursement pathway before launch
• Clear care setting and placement design
• Channel strategy that drives utilization
• Commercial operating infrastructure that supports scale

Without this architecture, companies enter the market unprepared for adoption.

Between validation and adoption sits a critical phase:

The market entry window.

This is where companies must translate:

• Clinical data into clinical utility
• Product capability into economic value
• Market access into actual utilization

Most companies underestimate this phase.

Some skip it entirely.

That is why so many diagnostics and devices reach the market but fail to scale.

The companies that succeed design for adoption before they launch.

They:

• Build reimbursement strategy alongside clinical development
• Align studies with payer and guideline expectations
• Define where and how the test or device will be used
• Engage channel partners early
• Build a repeatable commercial model

They treat clinical adoption as a system, not a phase.

Since entering the diagnostic and MedTech space in 2002, we have observed a fundamental shift in how markets form and how adoption actually occurs.

In the early 2000s, diagnostics operated in a product-first paradigm. A strong assay, a clear clinical need, and a capable sales team were often sufficient to build a commercial business. Reimbursement was simpler. Payer scrutiny was lower. The path from clearance to revenue was shorter and more forgiving.

That paradigm no longer exists.

Today, the market entry window demands an evidence-first architecture. Payers require clinical utility data before coverage decisions. Health systems require economic justification before formulary access. Physicians require workflow integration before behavior change.

The companies that recognize this shift early, and design for it, are the ones that achieve sustainable adoption. The companies that operate under the old paradigm, building a product and expecting the market to follow, are the ones that stall.

The market entry window has not closed. It has become architectural.

Key Takeaway

3 Steps to Bridge the Market Entry Window

1. 1

   Design evidence for utility, not just validation.

   Align clinical studies with the questions payers and health systems actually ask: does this change clinical decisions and reduce downstream cost?

2. 2

   Build reimbursement architecture before clearance.

   Define coding, coverage, and payment pathways in parallel with regulatory development. Waiting until post-clearance creates 12 to 18 months of preventable delay.

3. 3

   Architect adoption as a system, not a phase.

   Integrate workflow design, channel strategy, and commercial infrastructure from the start. Products that are easiest to adopt will outperform those that are most analytically precise.

Closing Perspective

FDA clearance is a critical milestone.

But it does not create demand.
It does not secure reimbursement.
It does not change clinical behavior.

Adoption must be architected.

Related Perspectives